<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01048034</url>
  </required_header>
  <id_info>
    <org_study_id>NMDSG08A</org_study_id>
    <secondary_id>2009-011483-11</secondary_id>
    <nct_id>NCT01048034</nct_id>
  </id_info>
  <brief_title>Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)</brief_title>
  <official_title>Clinical and Biological Evaluation of Azacitidine in Transfusion-dependent Patients With Low and Intermediate-1 Risk MDS, and Low-risk CMML, Who Are Either Refractory to or Not Eligible for Treatment With Erythropoietin +/- G-CSF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nordic MDS Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nordic MDS Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Azacitidine has proved prolonged overall survival in patients with high-risk MDS. Minor pilot
      studies have shown that treatment with Azacitidine can induce transfusion independency in
      previous transfusion dependent patients with low-risk MDS. This study will evaluate the
      effect of Azacitidine in transfusion dependent patients with low-risk MDS (IPSS low or int-1)
      or low risk CMML. Included patients should first have failed, or considered not being
      eligible to, treatment with EPO +/- G-CSF. Our hypothesis is that Azacitidine can lead to
      transfusion independency in this group of patients. Those patients who do not respond to
      treatment with Azacitidine alone, will be given treatment with the combination of Azacitidine
      and EPO where our hypothesis is that Azacitidine can restore sensitivity to EPO.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin level</measure>
    <time_frame>Week 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients reaching transfusion independency after treatment with Azacitidine</measure>
    <time_frame>Week 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect on leucocyte, platelet count</measure>
    <time_frame>Week 28 and End of Trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on bone marrow morphology and cytogenetics</measure>
    <time_frame>Week 28 and End of Trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients reaching transfusion independency after treatment with Azacitidine and Epo</measure>
    <time_frame>End of Trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on genetic and epigenetic profile</measure>
    <time_frame>Week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin level</measure>
    <time_frame>End of Trial</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Azacitidine +/- erythropoetin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>100 mg / m(2) subcutaneously day 1-5 every 4 weeks for 6 cycles. Another three cycles will be given together with epo for those not responding to the first 6 cycles of Azacitidine</description>
    <arm_group_label>Azacitidine +/- erythropoetin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythropoetin</intervention_name>
    <description>For those patients not responding to Azacitidine alone, the combination of Azacitidine and erythropoetin 60 000 U / week for 16 weeks will be given.</description>
    <arm_group_label>Azacitidine +/- erythropoetin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be 18 years of age at the time of signing the informed consent form

          -  MDS at IPSS Low or Int-1, or mixed MDS/MPD; either CMML with &lt; 10% marrow blasts or
             RARS-T

          -  Patients with high or intermediate probability for response according to the
             predictive model (see Hellstrom-Lindberg et al, Br J Haematol 99:344-51 1997)should be
             refractory to EPO / darbepoetin (equivalent to &gt; 60 000 U of EPO / week for &gt; 8 weeks)
             followed by EPO + G-CSF for &gt; 8 weeks, or biosimilar drugs in equipotent doses, or EPO
             + G-CSF upfront for 8 weeks. Patients with low probability for response according to
             the predictive model, could be included without prior EPO/G-CSF treatment

          -  Transfusion need &gt;4 units over the last 8 weeks, or &gt;8 units over the last 26 weeks.

          -  Subject has signed the informed consent document.

          -  Men and women of childbearing potential must use effective contraception during, and
             for up to 3 months after treatment.

        Exclusion Criteria:

          -  Pregnant or lactating females.

          -  Patients who are eligible for curative treatment

          -  Expected survival less than 24 weeks.

          -  Symptomatic thrombocytopenia / active bleeding

          -  Patients with JAK-2 positive RARS-T if eligible for new investigational drugs

          -  Serum biochemical values as follows

               1. Serum creatinine &gt;2.0 mg/dL (177 micromol/L)

               2. Serum aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) or
                  alanine transaminase (ALT)/serum glutamate pyruvate transaminase (SGPT) &gt;3.0 x
                  upper limit of normal (ULN)

               3. Serum total bilirubin &gt;1.5 mg/dL (26 micromol/L)

          -  Uncontrolled systemic infection

          -  Considered not capable of following the study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magnus Tobiasson, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Nordic MDS Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Hematology, Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Hematology, Aarhus Univsersity Hospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Hematology, Rigshospitalet Univsersity Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Hematology, Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Hematology, Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medcine, Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Hematology, Rikshospitalet University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medicine, Mälarsjukhuset Hospital</name>
      <address>
        <city>Eskilstuna</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of medicine, Falun Hospital</name>
      <address>
        <city>Falun</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medicine, Sahlgrenska University Hospital / Östra</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Hematology, Linköping University Hospital</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medicine, Sunderbyn Hospital</name>
      <address>
        <city>Luleå</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Hematology, Lund University Hospital</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Hematology, Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medicine, Södersjukhuset Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medicine, Umeå University Hospital</name>
      <address>
        <city>Umeå</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medicine, Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2010</study_first_submitted>
  <study_first_submitted_qc>January 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2010</study_first_posted>
  <last_update_submitted>October 28, 2013</last_update_submitted>
  <last_update_submitted_qc>October 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myelodysplastic syndrome</keyword>
  <keyword>Chronic myelomonocytic leukemia</keyword>
  <keyword>Transfusion therapy</keyword>
  <keyword>Transfusion dependency</keyword>
  <keyword>Hypomethylating therapy</keyword>
  <keyword>Azacitidine</keyword>
  <keyword>DNA-methylation</keyword>
  <keyword>Epigenetic modifications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

